These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 35573354)

  • 1. Cariprazine's Potential in Improving Social Dysfunction in Patients With Schizophrenia: A Perspective.
    Morozov P; Bekker R; Bykov Y
    Front Psychiatry; 2022; 13():868751. PubMed ID: 35573354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.
    Tarzian M; Ndrio M; Kaja S; Beason E; Fakoya AO
    Cureus; 2023 May; 15(5):e39309. PubMed ID: 37378203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cariprazine: an augmentation strategy for treatment-resistant schizophrenia with pro-cognitive and anti-hostility effects.
    Boydstun C; Lynch S; DiGenova P
    Int Clin Psychopharmacol; 2023 Sep; 38(5):361-366. PubMed ID: 37351582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety.
    Laszlovszky I; Barabássy Á; Németh G
    Adv Ther; 2021 Jul; 38(7):3652-3673. PubMed ID: 34091867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dopamine D
    Calabrese F; Tarazi FI; Racagni G; Riva MA
    CNS Spectr; 2020 Jun; 25(3):343-351. PubMed ID: 31010452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.
    Neill JC; Grayson B; Kiss B; Gyertyán I; Ferguson P; Adham N
    Eur Neuropsychopharmacol; 2016 Jan; 26(1):3-14. PubMed ID: 26655189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The novel atypical antipsychotic cariprazine demonstrates dopamine D
    Delcourte S; Ashby CR; Rovera R; Kiss B; Adham N; Farkas B; Haddjeri N
    CNS Neurosci Ther; 2018 Dec; 24(12):1129-1139. PubMed ID: 29729086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical potential of cariprazine in the treatment of acute mania.
    Altınbaş K; Guloksuz S; Oral ET
    Psychiatr Danub; 2013 Sep; 25(3):207-13. PubMed ID: 24048386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cariprazine - a novel antipsychotic drug and its place in the treatment of schizophrenia.
    Misiak B; Bieńkowski P; Samochowiec J
    Psychiatr Pol; 2018 Dec; 52(6):971-981. PubMed ID: 30659560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazine.
    Werner FM; Coveñas R
    Ther Clin Risk Manag; 2015; 11():1657-61. PubMed ID: 26586950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
    Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
    J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of negative symptoms in schizophrenia: update and proposal of a clinical algorithm.
    Cerveri G; Gesi C; Mencacci C
    Neuropsychiatr Dis Treat; 2019; 15():1525-1535. PubMed ID: 31239687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia.
    Watson DJG; King MV; Gyertyán I; Kiss B; Adham N; Fone KCF
    Eur Neuropsychopharmacol; 2016 Feb; 26(2):208-224. PubMed ID: 26723167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cariprazine, an orally active D2/D3 receptor antagonist, for the potential treatment of schizophrenia, bipolar mania and depression.
    Gründer G
    Curr Opin Investig Drugs; 2010 Jul; 11(7):823-32. PubMed ID: 20571978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cariprazine in Three Acute Patients with Schizophrenia: A Real-World Experience.
    Montes JM; Montes P; Hernández-Huerta D
    Neuropsychiatr Dis Treat; 2021; 17():291-296. PubMed ID: 33568908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study).
    Ivanov SV; Smulevich AB; Voronova EI; Yakhin KK; Beybalaeva TZ; Katok AA
    Front Psychiatry; 2021; 12():770592. PubMed ID: 35140638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Binding kinetics of cariprazine and aripiprazole at the dopamine D
    Frank A; Kiss DJ; Keserű GM; Stark H
    Sci Rep; 2018 Aug; 8(1):12509. PubMed ID: 30131592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cariprazine: A Review in Schizophrenia.
    Garnock-Jones KP
    CNS Drugs; 2017 Jun; 31(6):513-525. PubMed ID: 28560619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Third-generation antipsychotics: focus on cariprazine].
    Riva MA
    Riv Psichiatr; 2021; 56(2):1-9. PubMed ID: 34003178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.